Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma
A study for patients with Celiac disease using study drug AMG 714
Sponsor: Celimmune
Enrolling: Male and Female Patients
IRB Number: AAAQ4556
U.S. Govt. ID: NCT02633020
Contact: Maria Minaya: 212-305-5422 /
Additional Study Information: This research study is testing an investigational medication called AMG 714 for people with refractory celiac disease Type II. If youre at least 18 years of age, diagnosed with celiac disease, and you are still experiencing persistent or recurrent intestinal atrophy and gastrointestinal symptoms despite following a strict gluten-free diet for at least 6 12 months, then you may qualify to participate in this study and receive at no cost: Study medication (active drug or placebo) for refractory celiac disease Type II and study-related care and monitoring. To qualify, you must be adhering to a strict gluten-free diet for at least 6 months prior to enrollment and must continue to follow the gluten-free diet throughout the study.
This study is closed
Peter Green, MD
Do You Qualify?
Have you been diagnosed with celiac disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Maria Minaya